BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genopole® to Attend the Biotechnology Industry Organization (BIO) International Convention in Washington, DC, and Promote its Biotech Companies on the Global Stage


6/21/2011 7:26:44 AM

EVRY, France, June 21, 2011 /PRNewswire/ --


Genopole® (France's leading biopark in the city of Evry, located just south of Paris and home to 20 academic labs, 17 shared-access technical facilities and 66 biotech companies) will be attending (as it does every year) the BIO International Convention. The 2011 event is to take place in Washington, DC, on June 27-30.

The BIO International Convention is the largest global event for the biotechnology industry and constitutes a great opportunity for Genopole® to showcase its companies to potential international partners:

- Three Genopole® portfolio companies have recently listed on the stock market. Global Bioenergies (which is developing a process for producing biofuels from sugars or agricultural waste) has just raised 6.6 million on the Alternext by NYSE Euronext market in Paris. Novagali Pharma (a specialist in ophthalmological products) closed one of France's largest IPOs in 2010 by raising 22 million on the NYSE Euronext market. IntegraGen (working to identify genes involved in autism and cancer) completed a 6.7 million stock capital increase on Alternext. This takes the total amount of funds raised by Genopole® portfolio companies since 1998 (when the biopark was founded) to over 279 million.

- In 2010, Genopole® portfolio companies raised 47.8 million - a 190% year-on-year increase!

- Genopole® companies generated an estimated turnover totaling 140 million in 2010 - a 14% increase on 2009's sales of 124 million.

At BIO 2011, Genopole® will share the Medicen Paris Region cluster's booth (along with its partners) and is providing organizational support to three biopark companies:

- Metabrain specializes in collaborative research on the prevention and treatment of diabetes, obesity and Alzheimer's disease (http://www.metabrainresearch.com).

- Texcell offers services in the fields of viral safety and immunomonitoring. The company's US subsidiary was incorporated in 2008 (http://www.texcell.fr).

- Nokad is developing biomarkers that predict the risk of thrombosis(http://www.nokad-technology.com).

As France's leading biopark and with assistance from its institutional partners (Invest in France Agency, The Economic Development Agency, The Essonne Economic Agency, and Essonne Chamber of Commerce and Industry), Genopole® is both underpinning its companies' international business development activities and seeking to attract non-French companies to locate to the campus. This pro-active policy recently resulted in the arrival of the French subsidiary of New England Biolabs, a global leader in the production and the commercialization of life science research reagents.

About Genopole®

Genopole® is the leading French science park dedicated to life sciences. Its campus - near Paris - combines academic (CEA, CNRS, INRA, INSERM and the University of Evry-Val-d'Essonne) and private research laboratories, university/higher education facilities, biotechnology companies and an incubator for biotech start-ups. Genopole®'s priority is to promote therapy- and environment-focused biotech by providing optimal conditions for company growth and progress in research, the development of large-scale biological activities and to make France a major competitor in the world of science and industry. Additional information about Genopole® is available at http://www.genopole.fr

Booth 2505, French Pavilion, Hall A

Press relations : nicole.chemali@genopole.fr
Genopole® c ontacts : eric.lameignere@genopole.fr, Tel.: +33-685-914-398
gabriel.mergui@genopole.fr, Tel.: +33-680-940-455

BIO
press file: http://www.paris-region.com

SOURCE Genopole



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES